Liz Bhatt, M.S., M.B.A., is the President and Chief Operating Officer at Septerna Inc., a pioneering biotechnology company advancing novel therapies for metabolic and endocrine diseases through G protein-coupled receptor (GPCR) drug discovery. With a Master of Science in Biotechnology from Stanford University and a Master of Business Administration from the Wharton School of the University of Pennsylvania, Bhatt brings over 20 years of experience in the biotech and pharmaceutical industries. Her career began at Genentech, where she honed her expertise in clinical operations and regulatory affairs, progressing to leadership roles in program management and business development. Throughout her tenure, Bhatt has spearheaded transformative initiatives, including the successful launch of three FDA-approved therapeutics that generated over $2 billion in cumulative revenue. At Amgen, she led cross-functional teams in scaling manufacturing operations, reducing production costs by 30% while ensuring compliance with global standards. Her strategic acumen was instrumental in a $1.5 billion acquisition deal, earning her recognition as a "Top 40 Under 40" biotech executive by BioSpace. As President and COO at Septerna Inc., Bhatt oversees all operational functions, from R&D pipeline advancement to commercial strategy, driving the company's expansion into Phase II clinical trials for its lead GPCR-targeted candidates. Under her leadership, Septerna has secured $300 million in Series C funding and forged key partnerships with global pharma leaders, positioning the company for accelerated growth and breakthrough innovations in precision medicine.